Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (Vehicle) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate ANT-1401 in Crow's Feet

NCT01809964
View directory record Official record
Conditions
Lateral Canthal Lines, Crows Feet
Interventions
ANT-1401, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
7
States / cities
Birmingham, Alabama • Miami, Florida • Pinellas Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

NCT00752687
View directory record Official record
Conditions
Hepatitis C
Interventions
ABT-072, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis

NCT00529555
View directory record Official record
Conditions
Adult Periodontitis
Interventions
minocycline HCl 2.1%, Scaling and root planing
Drug · Procedure
Lead sponsor
Sunstar Americas
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Gainsville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Opthalmic Solution 0.75%, Placebo, Low dose pilocarpine, Low dose pilocarpine vehicle
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
40 Years to 64 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122
View directory record Official record
Conditions
Gorlin Syndrome
Interventions
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Rogers, Arkansas • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

CD-NP in Subjects With Stable Chronic Heart Failure

NCT00620308
View directory record Official record
Conditions
Stable Chronic Heart Failure
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abatacept for SLE Arthritis (IM101-330)

NCT02429934
View directory record Official record
Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
abatacept also known as Orencia also known as CTLA4-Ig, Placebo
Biological · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT02807428
View directory record Official record
Conditions
Post-surgical Pain
Interventions
AYX1 Injection 660 mg/6 mL, Placebo Injection 6 mL
Drug
Lead sponsor
Adynxx, Inc.
Industry
Eligibility
40 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

NCT05608343
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Difamilast, Placebo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

NCT02419508
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

NCT01134705
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
35
States / cities
Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

NCT03960866
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 3, 2026, 6:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pain and Acetaminophen in Women Study

NCT04573426
View directory record Official record
Conditions
Overweight, Obesity, Healthy Adults
Interventions
Acetaminophen, Placebo, Weight stigma vignette, Control vignette
Drug · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT03764735
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis

NCT02025725
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers

NCT01907776
View directory record Official record
Conditions
Healthy
Interventions
ME1100 inhalation solution, ME1100 placebo inhalation solution
Drug
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 3, 2026, 6:55 PM EDT
Recruiting Phase 3 Interventional

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

NCT07016750
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
KB803, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

NCT02670785
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions
Estradiol Vaginal Capsule (EVC), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

NCT04089735
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, APP13007, 0.1%, APP13007 Placebo, 0.05%, APP13007 Placebo, 0.1%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 3, 2026, 6:55 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

NCT00871208
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Altabax (R), Vehicle and Locoid lipocream (R)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
9 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

NCT01769755
View directory record Official record
Conditions
Crohns Disease
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 3, 2026, 6:55 PM EDT